Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharmaceuticals reported Q3 2026 total net product sales of $69.8 million, up 24% year-over-year and 38% sequentially, driven by Fanapt momentum and the early NEREUS launch. GAAP net loss was $22.6 million (diluted loss per share of $0.37), roughly flat versus the prior-year quarter, while operating expenses fell 18% sequentially to $93.3 million as Phase III and launch-preparation spend winds down. Cash and marketable securities fell to $140.5 million, down $123.4 million since year-end 2025, and the company guided full-year 2026 revenue above $240 million.
Key figures
- Revenue
- 69815000
- Guidance
- FY2026 total revenue greater than $240 million
- Revenue Yoy
- 24%
- Cash securities
- 140500000
- Fanapt sales q3
- 38765000
- Nereus sales q3
- 1612000
- Opex change qoq
- -18%
- Hetlioz sales q3
- 21689000
- Ponvory sales q3
- 7749000
- Quimilza pdufa date
- December 12, 2026
- Total operating expenses q3
- 93336000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.